在宣布的COVID-19患者中宣布的呼吸并发症的疗法的合作宣布

CN Bio宣布与墨尔本大学合作，重点是恢复COVID-19患者的呼吸疗法。该研究的目的利用CN Bio的器官芯片技术，是开发一种能够概括慢性间质性肺部疾病中纤维化和组织重塑的模型，通常发生在SARS-COV-2感染后发生。随后，大学将研究抗炎，抗纤维化和抗病毒药物以治疗患者。

对于患有COVID-19的慢性并发症的患者，已经确定了许多长期的健康作用，包括呼吸道并发症是由间质性肺部疾病引起的。through the collaboration, CN Bio’s Sydney-based distributor, AXT, will provide the University of Melbourne access to the Company’s proprietary PhysioMimix™ Organ-on-Chip system, to create a more human-relevant COVID-infected lung culture than current in vitro standards that use monkey fibroblasts. Led by Professor Alastair Stewart, the research team will adopt the lung model to elicit physiologically comparable inflammation and cytokine responses following drug testing; to support development of novel therapies, aiming to prevent a second wave of late mortalities associated with the medium-term morbidity.

to further improve translatability of the COVID-19 infected lung culture, CN Bio’s technology will enable researchers to create an organotypic air-liquid interface, which has more utility than the organoid approach, in which cilia within the structure make it difficult to study viral infection. Additionally, viable cell culture time is predicted to be prolonged (currently 1 week), allowing for an extended study of infection and pharmacology drug intervention.

“共同19-19大流行影响了每个人的生活；我们很荣幸运用我们的芯片能力来支持这项无价的研究，以解决其持续的并发症。Selection for this project by the University of Melbourne, one of the world’s top research institutions, is a privilege for our team,” commented Dr Audrey Dubourg, Product Manager, CN Bio.“We look forward to working with Professor Alastair Stewart and his group, who will be supported by our Australian distributor, AXT, leading experts in high-tech scientific equipment.”

墨尔本大学ARC个性化治疗技术中心主任Alastair Stewart教授表示：患者至关重要。利用CN Bio的微生物生理技术，我们希望增强我们对能够治疗患有呼吸系统并发症患者的药物的分子机制和药理作用的理解。”